Navigation Links
EnVivo Pharmaceuticals Names Stephen DiPalma Chief Financial Officer
Date:9/9/2009

WATERTOWN, Mass., Sept. 9 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the appointment of Stephen J. DiPalma as senior vice president and chief financial officer. DiPalma is responsible for overall financial operations for EnVivo including financial analysis, accounting and operations.

"EnVivo has grown to the point where we have created a CFO position to help better manage our broad pipeline and increasing business opportunities," said Kees Been, CEO of EnVivo. "Steve brings a broad skill set and a proven track record to the position that combines a strategic business perspective and an entrepreneurial spirit. We anticipate his 25 years of experience to be a great asset to EnVivo at this important time for our company."

Most recently, DiPalma was Executive Vice President of Business Operations and CFO for RXi Pharmaceuticals Corporation, a company focusing on RNAi therapeutics that he helped to bring public. He was also Co-founder, President and CEO of Catalyst Oncology which focused on personalized medicine approaches for multiple forms of cancer. Prior to RXi and Catalyst Oncology, DiPalma served as CFO at companies including Milkhaus Laboratories, Phytera, Aquila Biopharmaceuticals and Athena Diagnostics.

DiPalma has an MBA, with concentrations in finance and accounting, from Babson College, and received a Bachelor of Science degree in Business Administration from the University of Massachusetts.

About EnVivo Pharmaceuticals

EnVivo Pharmaceuticals, located in Watertown, Mass., is a biopharmaceutical company dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system, with a current focus on Alzheimer's disease, Cognitive Disorders and Schizophrenia. The company's lead product is EVP-6124, an alpha-7 nicotinic acetylcholine receptor agonist and has been tested in Phase IIa clinical trials for cognition disorders in Alzheimer's disease and Schizophrenia. The company's other programs include an epigenetics program based on Histone Deacetylase inhibition (HDACi) with EVP-0334 as the lead molecule for cognition in Alzheimer's disease which is in Phase I studies, and several preclinical programs such as a Gamma Secretase Modulator (for Alzheimer's disease) and a PDE10 inhibitor program (for schizophrenia). For more information about EnVivo, visit www.envivopharma.com.


'/>"/>
SOURCE EnVivo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EnVivo Pharmaceuticals Announces Results and Successful Completion of EVP-6124 Phase Ib/IIa Trial at the International Conference on Alzheimers Disease
2. EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimers Disease Transgenic Mouse Model With Gamma-Secretase Modulator
3. EnVivo Pharmaceuticals Announces Executive Appointment
4. Oramed Pharmaceuticals Commences Human Clinical Trials of an Oral GLP-1 Analog
5. Wilmington Pharmaceuticals Receives FDA Approval for Orally Disintegrating Metoclopramide Tablet
6. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Alexza Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Trubion Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
9. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
10. Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009
11. Onyx Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... , ... June 21, 2017 , ... ... and hiring top executive talent in the life sciences industry, today announces a ... company. The partnership takes full advantage of Beaker’s expertise in executive recruitment ...
(Date:6/22/2017)... ... June 22, 2017 , ... For the months of ... a Spotlight series on “Cell Therapy Regulation” for its regenerative medicine ... on the unique regulatory challenges of stem cell medical research. , Stem cell ...
(Date:6/20/2017)... ... 20, 2017 , ... CTNext , Connecticut’s go-to resource ... a Higher Education Entrepreneurship Advisory Committee to implement the recommendations of the master ... representatives from 35 higher education institutions across the state over the past six ...
(Date:6/20/2017)... ... June 20, 2017 , ... Do More with OHAUS ... from being a trusted supplier in the weighing industry, to extending its expertise across ... essays, enzyme reactions, immunoassays, hybridizations and more, allowing for its customers to ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... N.Y. , April 11, 2017 ... fingerprints, but researchers at the New York University ... College of Engineering have found that partial similarities ... security systems used in mobile phones and other ... thought. The vulnerability lies in the ...
(Date:4/5/2017)... KEY FINDINGS The global market for stem ... 25.76% during the forecast period of 2017-2025. The rise ... growth of the stem cell market. Download ... The global stem cell market is segmented on the ... cell market of the product is segmented into adult ...
Breaking Biology News(10 mins):